Date Insider Type Main position Quantity % Market Cap. Importance
10/23/23 Free

General Counsel

70,000 0.7479%
10/16/23 Free

Chief Financial Officer

151,416 1.6178%
9/15/23
Versi Group LLC
ConversionCompany 729,200 7.7913%
Change 5-day change 1-year change 3-year change Capi.($)
-99.00%-99.00% - - 10
+0.45%-5.74%+30.42%+127.69% 1,204B
+1.81%-4.91%+33.81%+81.26% 643B
+1.66%-2.29%+25.64%+108.42% 501B
-0.71%-2.03%+27.16%+67.19% 378B
+2.04%-7.98%+43.18%+32.43% 327B
+0.17%-4.83%+27.05%+51.38% 285B
+1.01%-3.72%-1.38%+33.21% 270B
+1.13%-5.17%+31.40%+66.43% 237B
+1.58%+0.69%+35.40%+122.68% 207B
Average -8.98%-4.40%+28.08%+76.74% 450B
Weighted average by Cap. +0.96%-4.71%+29.05%+89.09%
Logo DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation is a commercial stage neuro-biotech company. The Company is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. It is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Employees
12
  1. Stock Market
  2. Stocks
  3. DMKPQ Stock